NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
8 trialsNCT01248247 2022-01-12
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01370070 2017-01-13
MC1079
Chinese University of Hong Kong
Phase 2 Completed
NCT01249105 2016-03-10
MK-2206 for Recurrent Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01169649 2016-02-18
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01186705 2015-11-18
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01466868 2014-07-10
AKTIL
Centre Leon Berard
Phase 2 Terminated
NCT01240941 2013-08-20
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn